Twinaqt

Drug name: Lamivudine dolutegravir tablets (Dovito)

English name: Twinaqt

Indications

As a complete treatment regimen for adult patients infected with human immunodeficiency virus type 1 (HIV-1) who have no history of antiretroviral treatment and no known resistance-related mutations to any component of this product

Usage and Dosage

This product should be prescribed under the guidance of a physician with experience in the treatment of HIV infection.

Patients should be tested for HBV infection before or during starting to use this product. Individuals of childbearing potential should take a pregnancy test before starting to use this product [Drug for pregnant and lactating women]) Dosage

For adults, the recommended dose of this product is one tablet once daily.

Administration: Orally.

This product can be taken with or without food

Dosage adjustment

When combined with other drugs, due to drug interactions (for example: rifampicin, carbamazepine, oxcarbazepine, phenytoin, phenobarbital, St. John's wort, When dose adjustment is required for etravirine (without synergistic protease inhibitors), efavirenz, nevirapine, or tipranavir/ritonavir, dolutegravir single preparations should be used.

In these cases, physicians should refer to the dolutegravir product information. Miss a dose If the patient misses a dose of this product and there are more than 4 hours before the next dose, the patient should take this product as soon as possible. If it is less than 4 hours before the next dose, the patient should not take the missed dose and just take the medicine according to the regular dosing schedule. elderly patients There are limited data on the use of this product in patients 65 years of age and older. No dose adjustment is required. Renal Impairment Patients with creatinine clearance less than 50 mL/min are not recommended to take this product. No dose adjustment is required in patients with mild renal impairment. Hepatic Impairment No dose adjustment is required in patients with mild or moderate hepatic impairment (Child-Pugh Class A or B). Data are not available for patients with severe hepatic impairment (Child-Pugh class C); therefore This product is not recommended for patients with severe hepatic impairment.

Pediatric Population The safety and effectiveness of this product have not been established in pediatric patients. No data are available